Exabis Library
Welcome to the e-CCO Library!
DOP75: Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP75: Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP75: Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP75: Video capsule endoscopy may detect active small bowel Crohn's disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP75: Video capsule endoscopy may detect active small bowel Crohn’s disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
Wednesday, 24 June 2020, 12:03 PM by Eloise Lanaud
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP76: Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP76: No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s disease in a nationwide cohort
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP76: Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP77: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli Experience
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM